Wikidata

(Q64150004)

English

A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis

clinical trial

In more languages

Statements

short name
BREEZE-AD-PEDS (English)
0 references
title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients With Moderate to Severe Atopic Dermatitis (English)
0 references
medical condition
dermatitis
0 references
eczema
0 references
country
Argentina
0 references
Australia
0 references
Austria
0 references
Brazil
0 references
France
0 references
Germany
0 references
Hungary
0 references
Israel
0 references
Mexico
0 references
Poland
0 references
Spain
0 references
Switzerland
0 references
Taiwan
0 references
United Kingdom
0 references
start time
10 May 2019
0 references
end time
10 December 2020
0 references
number of participants
465
0 references
minimum age
2 year
0 references
maximum age
17 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q64150004&oldid=1857567816"